Cardiomyopathy Efficacy of Tafamidis in Patients with Ala97Ser Hereditary Transthyretin Cardiac Amyloidosis: A Six-Month Follow-Up Study
Journal
Acta Cardiologica Sinica
Journal Volume
39
Journal Issue
4
Pages
619-627
Date Issued
2023-07
Author(s)
Yu, An-Li
Wu, Yuan-Kun Aden
Chou, Chia-Hung
Abstract
Hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal disease. A97S (p.Ala117Ser) is the most common transthyretin genetic mutation in Taiwan. Tafamidis is a transthyretin stabilizer, and it has been shown to improve outcomes. However, its effect on A97S ATTR-CM subtypes remains unknown.
Subjects
Cardiomyopathy; Hereditary transthyretin amyloidosis; NT-proBNP; Tafamidis
SDGs
Type
journal article